Vimta Labs Ltd.

NSE: VIMTALABS | BSE: 524394 | ISIN: INE579C01029 | Industry: Healthcare Services
| Mid-range Performer
610.2000 8.70 (1.45%)
NSE Jan 02, 2026 15:31 PM
Volume: 68,768
 

logo
Vimta Labs Ltd.
18 Dec 2017
610.20
1.45%
Rudra Shares and Stock Brokers Ltd
Clinical research and testing - Major Revenue Contributor - Provide stability Company has presence in pre-clinical testing having an strong analytical skills and provides these services to pharma, bio-tech, animal health, Bio-similar clients and medical device companies. Analytical division contribute around 45% of revenues which provides better stability to the overall business. In clinical research and testing India is rapidly gaining market share over China due to better quality and technology protection laws. Also the innovators are now outsourcing these operations to low cost countries due to better cost economics. Due to these factors industry as a whole is expected to grow at a good pace which would be...
Number of FII/FPI investors increased from 36 to 43 in Sep 2025 qtr.
More from Vimta Labs Ltd.
All earning calls
Investor presentations from Vimta Labs Ltd.
All investor presentations